Blog
Insights on account research, sales intelligence, and B2B selling from the Salesmotion team.
What a Bioanalytical CRO Should Track, and What to Ignore
Most signal lists are written for full-service CROs. For a bioanalytical lab the useful set is much narrower: PK and bioequivalence starts, first-in-human, biosimilars, and the filings that fund them.
Should Your CRO Build a Claude Agent for Sponsor Research, or Buy One?
A build vs buy AI agent decision for life sciences BD teams: what a weekend agent on ClinicalTrials.gov genuinely does, what it cannot do, and the maintenance bill nobody quotes.
From Export to Chart: How CRO Leaders Build a Pipeline View by Indication and Phase
Business unit heads ask the same four questions about a therapeutic area. Here is the dataset that answers them, how to assemble it from trial registry data, and the four charts worth maintaining.
Territory Planning for CRO BD Teams, State by State
Country-level territories put half the US pipeline in one rep's patch. Here is how to build a state-level sponsor universe from registry data, balance it by trial volume rather than headcount, and keep it current.
How to Find Clinical Trial Sponsors Before They Pick a CRO
By the time an RFP lands, the decision is largely made. Here are the five registry events and three non-registry precursors that tell you a sponsor is approaching a CRO decision, and a weekly routine for working them.
GlobalData Alternatives for Mid-Size CROs
GlobalData is built for research and forecasting. A five to twenty person BD team has a different job. Here is an honest comparison by job to be done, what is publicly known about pricing, and how to switch without losing history.
Industry vs Academic Sponsors: Filtering University Hospitals Out of Your List
Most trial registry searches return a majority of academic sponsors. Here is how sponsor class actually works in the registry, why UK and EU results skew academic, and how to filter them out today.
One Seat, One Month: Running a Sales Intelligence Trial Inside a Large CRO
A single rep can prove or disprove a sales intelligence tool in thirty days without involving procurement. Here is the account selection, the weekly log, the four numbers a manager cares about, and a one-page report template.
Sterilization Decision Signals in Drug Development
Sterilization and packaging suppliers sell into a decision that happens once per programme. Here is where it sits on the development timeline, and the public signals that tell you a programme is approaching it.
Account Discovery vs. Account Intelligence: Two Different Products
Finding companies you have never heard of and knowing what to do with the ones you already target are different problems solved by different tools. Here is how to tell which one you need.
Bad Leads Kill Tool Adoption
Sales tools rarely fail on features. They fail when the first few outputs a rep checks turn out to be wrong, and the rep stops checking. How data quality determines adoption.
Best MCP Servers for Sales Teams (2026)
Every major sales vendor shipped an MCP server this year. A practical guide to what each one actually does, which combination is worth connecting, and why installing all of them makes your assistant worse.
Can't I Just Build This With Claude Code? An Honest Answer
Claude Code can genuinely build account intelligence now. Here is what the build actually involves, what breaks around month three, and the specific cases where building is the right call.
Clay MCP vs Salesmotion MCP: Two Different Jobs Inside Claude
Both connect Claude to GTM data. Clay MCP brings 150+ data providers and workflows into chat. Salesmotion MCP brings monitored account intelligence. Here is which question each one answers.
Finding Preclinical and Stealth Biotechs: What's Actually Discoverable
Preclinical companies leave a thin public trail. Here is exactly which signals exist before a trial registration, which do not, and how to build a discovery process around the real limits.
FullEnrich MCP vs Salesmotion MCP: Enrichment and Account Intelligence Are Not the Same Job
FullEnrich MCP runs a contact-data waterfall inside Claude. Salesmotion MCP brings monitored account intelligence. They answer opposite questions, and most teams should run both.
What Life Sciences BD Teams Get Wrong About Contact Seniority
Most contact databases skew toward the C-suite while the people who actually scope and select vendors sit two levels down. Why that happens, and how to target the real buying committee.
The Sales MCP Stack: Which Server Answers Which Question
MCP servers for GTM teams multiplied fast. A practical guide to which one answers which question, why installing all of them makes your assistant worse, and how to pick.
Selling Into Non-English Markets: Where Signal Coverage Breaks
Buying-signal tools are built on public web content, and that content is not evenly distributed. An honest map of where signal coverage is strong, where it thins out, and how to evaluate it for your territory.
Signal Relevance Beats Signal Volume
Pulling lots of data is table stakes. Deciding what matters is the hard part. How to evaluate a signal platform on relevance rather than coverage, and why volume metrics mislead.
Why Your AI SDR Pilot Failed
A post-mortem framework for AI SDR pilots that did not work. The four failure modes, how to tell which one you hit, and what to do differently before trying again.
Salesmotion MCP 4.0: Twelve Sales Skills and an Interactive Account Card, Inside Claude
Type 'account plan for Honeywell' and get the plan. MCP 4.0 adds twelve guided sales workflows, an interactive account card that renders inside Claude, four new company-intelligence tools, and workspace keys so a team connects with one shared key instead of a key each.
Account Monitoring Software: Your Guide to Winning Deals
Discover how account monitoring software helps revenue teams find buying signals, personalize outreach, and build pipeline. A complete guide for sales leaders.
Sales Intelligence Software: A Practical Guide for 2026
Discover how sales intelligence software helps revenue teams identify, engage, and convert high-value prospects.